Rilmenidine treatment in patients with mild to moderate arterial hypertension and metabolic syndrome

Rilmenidine treatment in patients with mild to moderate arterial hypertension and metabolic syndrome

Efficacy, tolerability and cardioprotective properties of rilmenidine were examined in patients with mild to moderate arterial hypertension (AH). The trial involved 51 hypertensive subjects, mean age 57,7+2,5 years. After wash-out period, rilmenidine was administered in the daily dose of 1-2 mg. At...

Full description

Bibliographic Details
Main Authors: S. S. Yakushin, N. I. Ivankova, N. S. Sazonova, N. V. Vilesova, G. O. Ivanova
Format: Article
Language:Russian
Published: «FIRMA «SILICEA» LLC  2004-12-01
Series:Российский кардиологический журнал
Subjects:
arterial hypertension
metabolic syndrome
cardioprotective effects
rilmenidine
Online Access:https://russjcardiol.elpub.ru/jour/article/view/2326
id doaj-58befe981e6e4afdadcb6b51a2dbe9d4
record_format Article
spelling doaj-58befe981e6e4afdadcb6b51a2dbe9d42021-07-28T14:02:06Zrus«FIRMA «SILICEA» LLC Российский кардиологический журнал1560-40712618-76202004-12-010657602072Rilmenidine treatment in patients with mild to moderate arterial hypertension and metabolic syndromeS. S. Yakushin0N. I. Ivankova1N. S. Sazonova2N. V. Vilesova3G. O. Ivanova4Рязанский государственный медицинский университет им. акад. И.П.Павлова; Рязанский областной клинический кардиологический диспансерРязанский государственный медицинский университет им. акад. И.П.Павлова; Рязанский областной клинический кардиологический диспансерРязанский государственный медицинский университет им. акад. И.П.Павлова; Рязанский областной клинический кардиологический диспансерРязанский государственный медицинский университет им. акад. И.П.Павлова; Рязанский областной клинический кардиологический диспансерРязанский государственный медицинский университет им. акад. И.П.Павлова; Рязанский областной клинический кардиологический диспансерEfficacy, tolerability and cardioprotective properties of rilmenidine were examined in patients with mild to moderate arterial hypertension (AH). The trial involved 51 hypertensive subjects, mean age 57,7+2,5 years. After wash-out period, rilmenidine was administered in the daily dose of 1-2 mg. At baseline and 12 weeks later, blood pressure (BP) and heart rate (HR) dynamics was assessed by the data from 24-hour BP monitoring (BPM), echocardiography, and biochemical blood assay. Good clinical efficacy and tolerability of albarel was observed, without disturbances of lipid, carbohydrate, electrolyte, purin metabolism, functional status of liver and kidneys. Rilmenidine treatment was also associated with EchoCG parameters improvement. Rilmenidine was effective and safe in arterial hypertension treatment, demonstrating cardioprotective properties as well.https://russjcardiol.elpub.ru/jour/article/view/2326arterial hypertensionmetabolic syndromecardioprotective effectsrilmenidine
collection DOAJ
language Russian
format Article
sources DOAJ
author S. S. Yakushin
N. I. Ivankova
N. S. Sazonova
N. V. Vilesova
G. O. Ivanova
spellingShingle S. S. Yakushin
N. I. Ivankova
N. S. Sazonova
N. V. Vilesova
G. O. Ivanova
Rilmenidine treatment in patients with mild to moderate arterial hypertension and metabolic syndrome
Российский кардиологический журнал
arterial hypertension
metabolic syndrome
cardioprotective effects
rilmenidine
author_facet S. S. Yakushin
N. I. Ivankova
N. S. Sazonova
N. V. Vilesova
G. O. Ivanova
author_sort S. S. Yakushin
title Rilmenidine treatment in patients with mild to moderate arterial hypertension and metabolic syndrome
title_short Rilmenidine treatment in patients with mild to moderate arterial hypertension and metabolic syndrome
title_full Rilmenidine treatment in patients with mild to moderate arterial hypertension and metabolic syndrome
title_fullStr Rilmenidine treatment in patients with mild to moderate arterial hypertension and metabolic syndrome
title_full_unstemmed Rilmenidine treatment in patients with mild to moderate arterial hypertension and metabolic syndrome
title_sort rilmenidine treatment in patients with mild to moderate arterial hypertension and metabolic syndrome
publisher «FIRMA «SILICEA» LLC 
series Российский кардиологический журнал
issn 1560-4071
2618-7620
publishDate 2004-12-01
description Efficacy, tolerability and cardioprotective properties of rilmenidine were examined in patients with mild to moderate arterial hypertension (AH). The trial involved 51 hypertensive subjects, mean age 57,7+2,5 years. After wash-out period, rilmenidine was administered in the daily dose of 1-2 mg. At baseline and 12 weeks later, blood pressure (BP) and heart rate (HR) dynamics was assessed by the data from 24-hour BP monitoring (BPM), echocardiography, and biochemical blood assay. Good clinical efficacy and tolerability of albarel was observed, without disturbances of lipid, carbohydrate, electrolyte, purin metabolism, functional status of liver and kidneys. Rilmenidine treatment was also associated with EchoCG parameters improvement. Rilmenidine was effective and safe in arterial hypertension treatment, demonstrating cardioprotective properties as well.
topic arterial hypertension
metabolic syndrome
cardioprotective effects
rilmenidine
url https://russjcardiol.elpub.ru/jour/article/view/2326
work_keys_str_mv AT ssyakushin rilmenidinetreatmentinpatientswithmildtomoderatearterialhypertensionandmetabolicsyndrome
AT niivankova rilmenidinetreatmentinpatientswithmildtomoderatearterialhypertensionandmetabolicsyndrome
AT nssazonova rilmenidinetreatmentinpatientswithmildtomoderatearterialhypertensionandmetabolicsyndrome
AT nvvilesova rilmenidinetreatmentinpatientswithmildtomoderatearterialhypertensionandmetabolicsyndrome
AT goivanova rilmenidinetreatmentinpatientswithmildtomoderatearterialhypertensionandmetabolicsyndrome
_version_ 1721269784499191808

Similar Items